IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation (vol 16, pg 975, 2020)-MedSci.cn

IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation (vol 16, pg 975, 2020)

Hack, SP

FUTURE ONCOLOGY, 2020; 16 (29): 2371

科室
- - 订阅+
  - 更多科室
工具
服务